Outcome of Board Meeting dated 27.02.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astonea Labs' board approved a variation in IPO object utilization, diverting Rs. 6.25 crore (16.59% of unutilized IPO proceeds) from original purposes like Bolivia registration and ointment plant machinery to acquire a 20-21% stake in Damaira Pharmaceuticals. The board also cleared omnibus approval for material related party transactions worth Rs. 415 crore for FY27, with the largest chunk of Rs. 271 crore going to Astonea One Private Limited. Other key approvals include adoption of new Articles of Association, relocation of registered office within Chandigarh effective April 1, 2026, and permission for loans/investments up to Rs. 100 crore. The board reversed earlier decisions to change the Registrar and Transfer Agent, confirming KFin Technologies will continue. An Extra-Ordinary General Meeting has been scheduled for March 27, 2026 to seek shareholder approval on these matters.
Shareholders should note the meaningful diversion of IPO funds toward a new acquisition not originally disclosed in the prospectus, plus the very large Rs. 415 crore related-party transaction envelope for FY27, which represents significant intra-group business activity and warrants close scrutiny at the upcoming EGM on March 27, 2026.